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ABSTRACT
Design Exploration and Analysis of Carbon-Infiltrated
Carbon Nanotube Vascular Stents
Darrell J. Skousen
Department of Mechanical Engineering, BYU
Master of Science
The purpose of this research was to design, develop, and test coronary stent designs composed of carbon-infiltrated carbon nanotubes (CI-CNTs). Coronary stents currently have two major
complications: restenosis and thrombosis. CI-CNT stents have potential to address both of these
issues, and therefore may provide improved clinical outcomes. CI-CNT stent geometry is patterned
using high-resolution photolithography that provide advantages in design possibilities.
To develop a coronary stent, a standard design process was followed including: background, design specifications, concept generation, development, analysis, and testing. Background
research was first completed and general design specifications for coronary stent performance were
compiled. Multiple design concepts were generated, evaluated, and finally a design was selected.
This stent design was further developed and optimized using analytical tools along with
finite element analysis. This stent design used tapered struts in repeating segments to reduce stress
and improve radial force. The design was modeled and analyzed as both a flat geometry as well
as in a cylindrical configuration. Mechanics of materials equations and geometry specific finite
element analysis were used to guide the final coronary stent design.
The stent design was tested mechanically, and additional tests were performed to verify
the blood compatibility of the CI-CNT material. The flat version of the stent design was manufactured and mechanically tested to verify performance. The performance of the cylindrical stent
configuration was analyzed using an FE model of an atherosclerotic artery. This arterial FE model
was created and validated by analyzing balloon angioplasty of a common stainless steel stent. The
biocompatibility of CI-CNTs was explored and studied. Blood compatibility testing of CI-CNT
samples was performed with results comparable in performance to stainless steel. A method of
stent deployment was planned, and several other stent design concepts were analyzed.
This research demonstrates that a functioning coronary stent can be manufactured from CICNTs. The optimized design has potential to address problems currently associated with stents.
However, a major challenge for CI-CNT stent designs is meeting the design requirement of sufficient radial force. CI-CNT stents also need to have excellent blood compatibility to justify being
used in stent applications.

Keywords: coronary stent, carbon nanotubes, blood compatibility, finite element analysis, compliant mechanism, pyrolytic carbon
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CHAPTER 1.

1.1

INTRODUCTION

Objective
The purpose of this research is to design, develop, and test coronary stent designs made of

carbon-infiltrated carbon nanotubes (CI-CNTs). Research on the current performance of vascular
stents was completed. Requirements for stent performance and methods for analyzing the stent
mechanical properties were also determined. Stent designs were generated and developed. FEA
and mechanical testing were performed to verify stent properties.
The specific objectives of this research are:
1. Design: Determine the required performance of a coronary stent. Generate concepts, and
select a basic design for a stent composed of CI-CNTs.
2. Develop: Optimize a basic repeating stent segment for a flat design. Use the optimized
segment to complete and analyze a full 3-dimensional cylindrical stent design.
3. Test: Analyze the stent design using analytical tools and using a finite element analysis.
Manufacture samples and mechanically test a flat version of the coronary stent. Perform
blood compatibility testing of CI-CNT material to predict stent biocompatibility.

1.2

Thesis Outline
This thesis is broken into five chapters. Chapter 1 provides background information on

the use of vascular stents, as well as information on the design requirements for coronary stents.
Chapter 2 includes the bulk of the research for this thesis. It includes the development of a coronary stent design, methods for analyzing stents, finite element analysis of both flat and cylindrical
designs, and results of mechanical testing. Chapter 3 includes information on the biocompatibility
of pyrolytic carbon as well as results of blood compatibility testing of CI-CNT samples. Chapter 4
1

Figure 1.1: Coronary Artery Disease. Top: normal coronary artery. Middle: narrowed coronary
artery. Bottom: narrowed artery with blood clot [4].

includes additional research on stent delivery systems as well as other design concepts. Chapter 5
includes a summary of contributions along with discussion of the thesis research.

1.3

Background
Cardiovascular disease is responsible for nearly one-third of all deaths in the world and

resulted in 17 million deaths in 2008 [12]. This disease results in over 800,000 deaths per year
in the U.S. and has an estimated cost of $503 billion per year with 51% of those deaths being the
result of coronary heart disease (CHD) [13].
The coronary arteries wrap around the heart and supply blood to the heart tissue. CHD is a
condition where the heart tissue isn’t receiving sufficient oxygen due to a reduced blood supply or
increased myocardial oxygen demand or both. Lack of oxygen in the heart tissue can lead to heart
failure and death. Coronary artery disease is the most common cause of CHD and is caused by a
narrowing and hardening of the coronary arteries due to the buildup of plaque on the inner arterial
walls (atherosclerosis) (Figure 1.1) [6]. As the arteries narrow, the blood flow is reduced causing
the heart to strain, which is felt by pain in the chest, fatigue, and shortness of breath. Plaque
may rupture or form a blood clot (thrombosis) that may break off from the vessel and completely
occlude the artery causing a heart attack.
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1.4

Treatment
Proper treatment of CHD can greatly decrease the risk of complications and death. If

detected early, CHD can be successfully treated by lifestyle changes including dieting, exercise,
and managing stress and other harmful behaviors. Also, drug therapy including the use of anticoagulants (blood thinners) to lower cholesterol and blood pressure can help prevent CHD related
complications.
Often, non-invasive methods are insufficient, and a more direct approach must be taken.
One of the first methods, and also one of the most common methods for treating severe CHD is
coronary artery bypass grafting [6]. This is a traumatic surgery (open-heart surgery) where the
chest is opened up and veins or arteries from other parts of the body are grafted to the coronary
artery system bypassing the diseased areas.

1.4.1

Percutaneous Coronary Intervention (PCI)
Over the past 30 years a much less invasive method for treating CHD has been developed

with considerable success. This method is called percutaneous coronary intervention (PCI). For
this treatment, an incision is typically made in the femoral artery in the thigh. A catheter is inserted
into the femoral artery and guided into the aorta to the desired coronary artery branch. A guidewire
(typically 0.014”) is advanced through the catheter and into the coronary artery to the diseased
vessel. A balloon catheter is advanced over the guidewire and positioned in the narrowed vessel.
The balloon is inflated for a short period of time, crushing and permanently deforming the plaque
and expanding the artery [6].
After balloon dilation, another balloon with a stent mounted on it is placed in the affected
artery. A stent is a cylindrical scaffold wire mesh, typically made of stainless steel. The stent is
deployed by inflating the balloon, causing the stent to expand and plastically deform. The balloon
is removed but the stent stays in place pushing against the artery wall keeping the artery open
permanently (Figure 1.2).
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Figure 1.2: Coronary stents are mounted on a balloon and positioned in a clogged artery. The
balloon is inflated causing the stent to permanently expand. The balloon is removed but the stent
remains in the body holding the artery open [5].

1.4.2

Drug Eluting Stents
Over the past 10 years, drug-eluting stents (DES) have been introduced. These stents are

similar in design to bare-metal stents, but they also are coated with anti-proliferative drugs. These
drugs release directly to the affected arteries to improve blood compatibility and reduce complications.

1.5

PCI Performance and Challenges
There are two major complications associated with PCI: restenosis and thrombosis. Resteno-

sis is much more common than thrombosis but is also less lethal. Restenosis is defined as the
renarrowing of the diseased vessel after PCI, and usually occurs within a few months [6]. Binary
restenosis is defined as the reduction in the minimal lumen diameter by greater than 50%, and is
usually measured during an angiogram. Clinical restenosis is defined as the rate of repeat revascularization of the same vessel after successful PCI. Binary restenosis rates are typically higher than
clinical rates (Table 1.1), but are also more difficult to measure, since this requires a follow-up
angiogram for each patient.
Restenosis from balloon angioplasty is caused by a combination of early elastic recoil,
negative remodeling, and neointimal formation. Early elastic recoil occurs immediately after balloon dilation, and is due to the elastic properties of the plaque and arteries. Late lumen loss
4

Table 1.1: Bare metal stenting vs balloon angioplasty [1].

in balloon angioplasty is caused by neointima formation (20-30%) and negative remodeling (7080%) [14, 15]. Neointima formation (sometimes referred to as intimal hyperplasia) is caused by
smooth muscle cell migration and proliferation. Negative remodeling is not completely understood, and results in a concentric compression of the outer layer of the blood vessel and may be
related to a thickening of the artery wall [16].
Table 1.1 shows the results of a large clinical trial showing the performance of bare-metal
stents against balloon angioplasty alone. Balloon angioplasty alone has a binary restenosis rate of
25-60%, while bare-metal stents have reduced restenosis to 10-30% [6].
In vascular stents, the elastic recoil and negative remodeling are prevented and in-stent
restenosis is almost entirely caused by neointimal hyperplasia inside the stented coronary artery
(Figure 1.3). This is mainly due to vessel wall injury causing an inflammatory response and delayed
endothelial healing of the stented segment [6, 17]. Figure 1.4 shows the possible outcomes of stent
and balloon angioplasty. The stent struts cause an inflammatory reaction which is related to the
trauma done to the vessel wall during PCI. The degree of injury during the procedure has been
shown to correlate with the degree of intimal hyperplasia [18, 19].
Two common drug-eluting coronary stents that have been studied in several clinical trials
are the Cordis BX Velocity (Table 1.2) and the Boston Scientific TAXUS stent (Table 1.3). In
two large clinical trials (1000+ patients), the TAXUS and BX Velocity stents greatly improved the
restenosis results as indicated in the target lesion revascularization (TLR) rates (Approx. 16% for
bare-metal stents and 4% for DES). These clinical trials are of single non-complex lesions and are
a best case scenario for stent results. From 1-year clinical trial results, DES have nearly completely
prevented restenosis from occurring in non-complex lesions [6].
5

Figure 1.3: In-stent restenosis is the result of intimal proliferation in and around a coronary stent
[6].

Figure 1.4: The upper pathway shows the possible outcomes for balloon angioplasty with no stent.
The lower pathway shows the pathway with a stent implanted [6].
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Table 1.2: Bx Velocity Stent Clinical Trial Results [2].

Table 1.3: Taxus Stent Clinical Trial Results [3].

Coronary thrombosis is defined as the formation of a blood clot inside of a coronary artery,
which can completely occlude the vessel causing myocardial infarction (heart attack). Thrombosis
rates within a year after stent angioplasty are typically less than 1% in clinical trials [2,3]. It is very
rare for thrombosis to occur in bare-metal stents after a month. However, even though drug-eluting
stents have drastically improved restenosis rates, they have resulted in an increase in late term
(after 1 month) thrombosis events [20–22]. Due to the high fatality rate associated with coronary
thrombosis, this is a major concern with drug-eluting stents.

1.6
1.6.1

Materials
Application of Pyrolytic Carbon
Ceramics are often useful in biomedical devices because of their excellent biocompatibility.

Pyrolytic carbon (PyC) is a biocompatible ceramic that is resistant to blood clotting. PyC is a
7

Figure 1.5: Pyrolytic carbon is used in many different biomedical applications including heart
valves [7].

popular material for biomedical implant devices, and has been used in more than 4 million heart
valves with over 25 different design configurations [10].
The blood compatibility of PyC has been tested extensively and has been shown to perform
as well as or better than stainless steel and titanium [23–25]. There is also interesting research into
further improving its blood compatibility through protein adsorption treatment [10].
Due to its brittle nature, PyC is difficult to use as a stent material. However, several stents
have been developed made of stainless steel or cobalt-chrome with a carbon coating to help improve blood compatibility [26, 27].
The majority of stent materials, with the exception of nitinol, must undergo large plastic
deformation in order to deploy in a blood vessel. It is difficult to design a stent composed entirely of
a ceramic material such as PyC that also has the mechanical performance necessary to successfully
treat CHD.

1.6.2

CI-CNT Fabrication
A form of PyC has been developed at BYU that allows high manufacturing tolerances

(1-3 micron) and also has excellent mechanical properties. This form of PyC is known as carbon-
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infiltrated carbon nanotubes (CI-CNTs). It is manufactured by growing a forest of carbon-nanotubes
and then infiltrating the carbon nanotubes with carbon graphite.
Using MEMS manufacturing processes, a mask can be made with a detailed 2-dimensional
geometry. Carbon-nanotubes are grown vertically extruding the 2-dimensional geometry into a
3-dimensional carbon-nanotube forest. The forest is then infiltrated with carbon graphite by a
vapor deposition method. The mechanical properties as well as the mass is dominated by the filler
material [28]. The biocompatible properties of the CI-CNTs is expected to be similar to other
methods of manufacturing PyC.

1.7

Coronary Artery Characteristics
For the majority of published clinical trials, only three coronary arteries were used in angio-

plasty procedures: left anterior descending, left circumflex, and right coronary arteries. From three
major clinical trials the percentage of lesions were left anterior descending (42%), left circumflex
(27%), and right coronary artery (31%). The average reference vessel of three major clinical trials
was 2.77 mm, with a minimal lumen diameter before treatment of 0.91 mm. The average lesion
length was 14.2 mm [2, 29, 30].

1.8

Mechanical Performance
Coronary stents must be able to expand to approximately three times their original diam-

eter [31]. The stent must have a crimped (compressed) profile as small as possible. Typically, a
coronary stent profile is 1.2 mm or less. This allows the stent to be easily manipulated and positioned in the body. Since the minimum lumen diameter is often close to 1 mm, a larger stent profile
would make it very difficult to insert into a clogged artery. The stent must be able to expand up to
2.5 to 4.0 mm to keep the stent open.
Bending stiffness is also critical for stent delivery. A less stiff stent is desirable because it
is easier to manipulate and move through tortuous anatomy. However, a lower bending stiffness is
often a competing requirement with a high radial stiffness. Several methods and tests have been
developed to determine the mechanical performance of coronary stents [31].
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1.9

Stent Applications
Coronary stents are a very common type of stent; however, there are many other uses and

possibilities for CI-CNT stents. Essentially, any vessel in the human body can become occluded
and cause complications. Nearly any occluded vessel can be treated with angioplasty and stenting,
including the biliary duct, ureter, and many other vessels.
Several stent applications are listed below:
Ureteral Stents
Ureteral stents are used to allow urine drainage through the ureter when it becomes blocked,
preventing damage to the kidney. One major problem with current ureteral stents is encrustation
where bacteria form a biofilm layer on the stent surface. These encrustations can cause stent
obstruction and impaired urine flow [32]. The Dolcera market analysis for ureteral stents estimates
that 92,000 stents are used a year for kidney stones, kidney transplants, and urinary incontinence
[33].
Prostatic Stents
Prostatic stents are used to allow drainage of urine for men. Often this is caused by an enlarged prostate that pushes against the urethra blocking it. These stents are often made of titanium
or titanium alloys [34].
Esophageal Stents
Esophageal stents are used to relieve difficulty in swallowing, often because of esophageal
carcinoma (cancer in or near the esophagus). Stents are made from both plastic and metal [35].
Biliary Stent
Biliary stents are placed in the bile ducts to treat obstructions and allow drainage of bile.
Several conditions cause bile duct obstruction, including cancer of pancreas, gallbladder, and other
surrounding organs. Also gallstones and injury to the gallbladder during removal surgery can
constrict the bile duct. These stents are made of both plastic and metal.
Femoropopliteal Stents
Stents are placed in the superficial femoral and popliteal arteries to allow better blood
flow to the legs. Claudication (pain in the leg brought on by walking) is more common in the
elderly, and can be relieved by angioplasty and stenting. Both nitinol and stainless steel stents have
been used, although angioplasty alone seems to deliver as good of results as stenting [36]. Cook
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Medical has recently developed the Zilver PTX DES that has shown to perform better than bare
metal stents [37].
While coronary stents are the most common type of stents and represent the largest market,
it is possible that CI-CNT stents will have advantages in other stent applications. Several of these
applications have similar challenges as coronary stents such as insufficient material biocompatibility. With proper design and development these issues could potentially be improved by using
CI-CNTs.

1.10

Conclusion
From this research, it is clear that while coronary stents perform fairly well, there is room

for improved performance that CI-CNT stents may provide. This background information was
necessary to understand the performance requirements and to benchmark the current success of
coronary stents. This research was used to design, develop, and test CI-CNT stents.
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CHAPTER 2.

2.1

CORONARY STENT DESIGN, OPTIMIZATION, AND ANALYSIS1

Abstract
In this chapter, coronary stent designs composed of CI-CNTs were developed and analyzed.

There is a need for new stent designs that can improve on complications that currently affect
coronary stents including restenosis and thrombosis. General design specifications for coronary
stents were researched and compiled to evaluate stent performance. Stent design concepts were
generated and evaluated.
One stent design was further developed and optimized using analytical tools along with
finite-element analysis. This stent design was modeled and analyzed in both a flat geometry as well
as cylindrical. The flat design was manufactured and mechanically tested to verify performance.
An FE model of an atherosclerotic artery was created and used to predict performance of the
cylindrical stent design.

2.2

Introduction
Coronary stenting can greatly reduce complications in coronary artery disease. However,

as with all implanted materials, the biocompatibility of the materials has a large effect on performance. Arterial restenosis and thrombosis are two serious complications that can occur after stent
angioplasty and are mainly due to the biocompatibility of the stent material, stent geometry, and
the degree of injury caused during insertion [16, 18, 19].
Drug-eluting stents (DES) have been introduced that have proven to reduce the occurrence
of restenosis [2, 3]. DES are often coated with an anti-proliferative drug that releases over a relatively short time (1-3 months) [38, 39]. A coronary stent that can improve blood compatibility
without the use of anti-proliferative drugs could improve stent performance.
1 Parts

of this chapter will be submitted in a journal article.
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Carbon Infiltrated Carbon Nanotubes (CI-CNTs) is a material that has been developed recently. It has excellent flexibility and elastic strain to failure, but exhibits almost no plasticity [40].
Its material composition is a form of pyrolytic carbon, which has been shown to have relatively
good blood compatibility [9, 24].
The majority of vascular stents used are made of stainless steel, cobalt chrome, or nitinol.
These stents, with the exception of nitinol, are manufactured in a crimped state (low profile). They
are inserted into the coronary artery mounted on balloon catheter and are plastically deformed
outward using balloon angioplasty to open the occluded coronary artery.

2.3

Design Specifications
The FDA has outlined many of the required attributes of vascular stents including: radial

stiffness/force, stent recoil, stress/strain analysis, biocompatibility and many other attributes [41].
Of these, the radial stiffness/force and the stress/strain analysis are critical to a functional stent design. Biocompatibility is also critical but is usually tested in-vitro, whereas mechanical properties
can be studied using finite-element analysis (FEA) as well as mechanical testing.
Stent radial stiffness and radial strength determine the ability of the stent to resist collapse
under loads [41]. This is critical because of the necessary forces the stent must provide against the
artery wall to prevent restenosis of the vessel after a procedure.
Restenosis from balloon angioplasty as described in Chapter 1 is caused by a combination
of early elastic recoil, negative remodeling, and neointimal formation. Stents prevent elastic recoil
and negative remodeling but neointimal hyperplasia is still a major problem. Figure 2.1 shows the
possible outcomes of stent and balloon angioplasty.
A coronary stent must be able to expand 2-4 times its original diameter. However, very
few materials can withstand greater than 100% strain without failure. For this reason, coronary
stents are designed with a geometry that allows a large geometrical expansion with a much smaller
material strain.
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Figure 2.1: The upper pathway shows the possible outcomes for balloon angioplasty with no stent.
The lower pathway shows the pathway with a stent implanted.

2.4

Stent Design
As with the development of any new concept, a general process must be followed in order

to develop a good design. This includes: defining the problem, background research, concept
generation, concept selection and analysis, and prototyping and testing. Chapter 1 defines the
problem and gives background research.
Our team performed concept generation and came up with many different design ideas.
These concepts were discussed and examined and more improved designs were generated. Some
of the more promising design concepts are provided in Chapter 4 and in Appendix A. Several
designs had promising performance, but their delivery or functionality was significantly different
than current stents. Several concepts included an ability to lock into an expanded configuration.
However, these concepts cannot be delivered and implanted as easily as current coronary stents.
One of the most promising stent concepts has a similar design to current coronary stents,
but is designed to provide maximum radial force. It is necessary to provide the maximum amount
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Figure 2.2: A coronary stent has repeating segments in both the circumferential and longitudinal
directions [8].

of force due to the lower elastic modulus and ultimate strength of CI-CNTs compared to current
stent materials.
Nearly all coronary stents have the same basic features as shown in Figure 2.2. Stents have
thin struts that are connected in a zigzag pattern. The connection between the struts has a circular
end radius to reduce the stress concentration at the connection. The struts and connection form a
basic stent segment that is repeated circumferentially around the stent.
To simplify the geometry, a stent design can be reduced into a basic stent segment Figure 2.3. This basic segment can be described by five parameters: strut thickness, strut length, strut
angle (theta), end radius, and end radius angle (phi). Phi is defined as the angle between the strut
and the tangent line of the end radius (phi is zero when the strut and end radius are tangent).
Stent struts are very thin compared to the overall diameter of the stent. For this reason, for
simple analyses the stent behaves like a thin-walled cylinder. The basic repeating stent segment is
nearly flat, and the stresses and mechanical behavior are nearly identical between a flat segment,
and a segment with a slight curvature. The design that was investigated and developed used this
basic repeating segment to design the stent.
CI-CNTs are a brittle material that cannot withstand plastic deformation. For that reason,
the stent can only undergo elastic deflection. Stainless steel and cobalt chrome stents are manufactured in a crimped state with diameter ≈ 1 mm, and then plastically expanded to a diameter ≈ 3
mm. Since CI-CNTs are fully elastic, the stent must be manufactured in its expanded shape, then
15

Figure 2.3: A basic stent segment can be described by five parameters: strut thickness, strut angle,
strut length, end radius, and end radius angle.

compressed down for insertion into the arteries. After it has been positioned in the correct location,
the stent is allowed to spring back to its original shape to hold the coronary artery open.
The design criteria of a fully elastic stent is substantially different than a plastically deformed stent. An optimized design is subject to a maximum allowable stress. From initial testing
of the CI-CNT material, a maximum tensile stress of 100 MPa and a maximum compressive stress
of 150 MPa can be expected [40]. A higher compressive strength is achieved because of the brittle
nature of the CI-CNTs.
The stent is required to deflect from an initial diameter of 3 mm to a compressed diameter
of 1 mm. This is equivalent to a 67% compression of each stent segment. A length of 1 mm
was selected for the struts which is typical for coronary stents to allow longitudinal flexibility. By
making the thickness very small, the stresses were lowered as much as necessary. However, as the
thickness decreases so does the radial stiffness/force of the stent. Elastic stents inherently have a
lower radial stiffness than plastically deformed stents, and therefore a maximum radial stiffness is
optimal.
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Figure 2.4: A basic stent segment can be analyzed into four equivalent fixed-free sections, where
the end radius is split and fixed and the strut is split and left free.

2.4.1

Stent Segment Optimization
The stresses and reaction forces for the basic stent segment can be calculated using mechan-

ics of materials equations and the pseudo-rigid-body model for compliant mechanisms [42, 43].
Due to the symmetric nature of the basic stent segment, only a quarter of that segment is needed
for analysis because the end radius can be split in two and fixed as shown in Figure 2.4.
This simplified model can be analyzed in two parts. First, the strut is chopped at the connection of the strut to the end radius. This strut can be represented as shown in Figure 2.5, with
a force on one end being counteracted by an equal and opposite force at the other end as well as
a bending moment. The second part is a partial ring that is fixed at one end, and loaded with the
same force and moment as the strut at the other end.
The two conditions can be analyzed fairly easily. The forces and moments of the strut were
calculated using the pseudo-rigid-body model. The stresses in the ring were calculated using thick
curved beam equations which accurately predict higher compressive stresses on the inner radius
of the ring. The stresses, forces, and deflections were calculated using MATLAB v.2012a (code
attached in Appendix B).
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Figure 2.5: The quarter segment can be analyzed in two parts, a straight beam and a partial ring.

2.4.2

Stent Segment Results
The basic stent segment was optimized using an exhaustive search method where each

continuous variable was assigned discrete values at 5 degree increments for theta and phi, and at
5 micron increments for the radius and thickness. The tensile stresses at the outer edge of the
ring and the compressive stresses at the inner edge of the ring as well as the reaction force were
calculated for each combination of variables. The constraints allowed a tensile stress less than 80
MPa, a compressive stress less than 120 MPa, and no physical contact (clash) between the stent
segments.
The stress concentration at the connection between the end radius and strut would result in
high tensile stresses, and a fillet would be needed there in a final design. However, to make the
analysis simpler to perform, the stresses at the connection were ignored. Later, in FE modeling a
fillet was added and the stresses at the connection were analyzed.
The results of the optimization are shown in Figure 2.6 and led to several key stent design
fundamentals. The thickness had large effect on both the stresses and the reaction force. A larger
thickness increased both the stress and the force. Therefore, the optimal design had the largest
possible thickness without exceeding the allowable stress.
The strut angle (theta) created higher forces when increased but much higher stresses.
Therefore, the optimal strut angle was the smallest possible angle that could be achieved without the segments clashing before reaching a 67% compression.
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Figure 2.6: Optimization of the basic stent segment with maximum force as the objective. Feasible
region is shaded in the upper left section. Each grid intersection point represents an individual
design. In this plot, the radius and radius angle were held constant while the thickness and strut
angle were variables. The feasible design space is in the upper left section with an optimum of:
Length (1 mm), Thickness (.025 mm), Theta (30 deg), Radius (.05 mm), and Phi (80 deg).

The end radius had lower stresses when the radius was larger. However, clash generally
occurred when the end radii of adjacent stent segments were larger causing them to run into each
other. Therefore, a more optimal design had a smaller radius. The smaller the radius, the more the
end radius behaved like a thick curved beam. As the radius was reduced the compressive stresses
on the inner edge of the radius became too high limiting how small the radius could be.
The connection angle (phi), had a small effect on stress. A larger phi lowered the stresses,
but if it became too large, the two struts would clash. The optimal parameters for this specific set
of parameters are: Length (1 mm), Thickness (.025 mm), Theta (30 deg), Radius (.05 mm), and
Phi (80 deg). A radial depth of .025 mm was used to determine the reaction forces.

2.4.3

Finite Element Analysis
The basic stent segment was analyzed with FEA using ANSYS V.13.0 software. The stent

was modeled as a solid volume with fillets added at the sharp connection between the end radius
and the strut (Figure 2.7). The basic stent segment was modeled using 21,700 Solid185 elements.
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Figure 2.7: Stent mesh used for FEA.

Table 2.1: FEA results for basic stent segment compared to calculations using mechanics of materials equations in MATLAB.
Description
Mechanics Equations
FEA, Control
FEA, Fine Mesh
FEA, Solid186

# of Elements

Max Tensile
Stress (MPa)

Max Compress
Stress (MPa)

Reaction
Force (mN)

Deflection
(mm)

Element
Type

1st P Stress
(MPa)

N/A
21,708
172,656
21,708

78.3
75.7
78.3
81

-112
-105
-110
-116

0.405
0.410
0.409
0.409

0.401
0.401
0.401
0.401

N/A
Solid185
Solid185
Solid186

88.5
92.9
96.9

N/A

Table 2.1 compares the results of the FE analysis to the results from the mechanics of materials
equations in MATLAB.
The max tensile and compressive stresses occur at the outer and inner edges of the end
radius, respectively, as predicted by the hand calculations. Three FE analyses were run on the
basic stent segment: a control mesh of 21,700 elements, a fine mesh with 172,600 elements, and
also using the higher order Solid186 20-node brick with 21,700 elements. Table 2.1 shows that the
results of the FEA and the hand calculations had good agreement on the predicted stresses (within
4%). Also, increasing the element size did not significantly change the FEA results. The reaction
forces showed excellent agreement as well. Displacement was used as the input and is equivalent
to 67% compression of the stent segment.
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Figure 2.8: Left: Stent stresses at the end radius showed high tensile stresses at the outer edge
(red), and high compressive stresses at the inside edge (blue). Right: The highest tensile stress
occurred at the filleted connection of strut to end radius.

The FEA analysis revealed that the tensile stresses at the filleted connection were higher
than at the end radius. The 1st principal stress was 88.5 MPa, considerably higher than 75.7 MPa.

2.5

Tapered Maximum Force Design
FEA of the basic stent segment in the previous section showed good agreement with the

predicted stresses and forces. However, the five parameter design was a very simple approach to
optimizing the stent geometry. The basic design had several flaws including high stress concentrations at the end radius and filleted connection. It also had a low reaction force which would give
the stent a low radial stiffness. The basic design could be improved using FEA techniques. The
following sections describe the optimization process used to improve the stent geometry, as well
as the results of mechanically testing manufactured samples of the final design.

2.5.1

Design Optimization
To improve the stent design, a tapered beam was used instead of a beam with constant

thickness. For the same deflection, a thinner beam has less stress than a thicker beam. Also, for the
same force, a thin beam will deflect more than a thick beam. These principles were used to taper
the beam in a way that spread the stress out more uniformly.
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A potential problem with the five parameter design is that adjacent segments could clash
together under smaller deflections than desirable. The segments clashed usually at only one location while the rest of the geometry had large gaps between segments. To improve this, the struts
were changed from being straight to slightly curved.
Due to the added complexity of tapering and non-straight geometry, mechanics of materials
equations were impossible to apply to analyze the stresses and forces. The only method that could
be used to quickly and efficiently improve the design is FEA. Fortunately, for simple geometries
the FEA had already shown to agree with the predicted results. It could reasonably be expected to
have accurate results when applied to more complex geometries.
Since this design is used in a cylindrical stent geometry, a few modifications to the design
specifications were made. Also, since this design was finalized several months after the five parameter design, our understanding of the design specifications as well as the material properties
improved.
This stent was designed for a coronary artery with an unoccluded inner diameter of 3 mm
(reference diameter). For this diameter, the stent was designed to have 12 circumferentially repeating segments. An initial outer diameter of 3.2 mm and a compressed diameter of 1.2 mm were
chosen resulting in a compression of 65%. The stent radial depth was chosen to be 100 microns,
which is in the typical range for coronary stents. Also, with a better understanding of the material
properties of CI-CNTs, higher compressive stresses were allowed. The stent was designed to have
a max compressive stress of 180 MPa and a max tensile stress of 90 MPa.
A manual trial and error approach was used to optimize the tapering and curvature of the
stent design. An automated approach would have been very difficult and time consuming to attempt
to program. Also, the concepts for an improved design were discovered using trial and error
methods. The design is simple enough that ANSYS was able solve each design iteration in a few
minutes.
After many analyses were performed, a final design was selected where trial and error could
no longer improve the design. It was named the tapered maximum force (TMF) design and two
adjacent segments are shown in Figure 2.9.
FEA of the stent design shows that the stresses were much more uniformly spread out
across the stent surface (Figure 2.10). Adjacent stent segments did not clash together. Even though
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Figure 2.9: Two adjacent segments of the tapered maximum force (TMF) design in the uncompressed configuration.

Figure 2.10: FEA of the TMF design reveals that the tensile stresses (1st principal) are spread out
more uniformly. The design does not clash together even under a 65% compression.

the struts were curved initially, when they were compressed they become nearly flat. The max
tensile stress was 82.1 MPa, with a max compressive stress of 165 MPa. The reaction force was
9.1 mN. Even after accounting for a change in radial depth and the overall length of the stent
segments, the TMF stent design showed more than a 3 fold increase in the reaction force over to
the original design while only slightly increasing the maximum tensile stress.
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Figure 2.11: Flat version of a full stent using the TMF design. This design was manufactured and
used in mechanical compression testing.

2.5.2

TMF Design Mechanical Testing Analysis
After the TMF design was completed, mechanical testing was needed to verify the me-

chanical performance matched the performance predicted from FEA. Kris Jones contributed to
this research in designing and constructing a method for testing, manufacturing test samples, and
conducting and analyzing the mechanical tests.
To test the TMF design, a flat version of a full stent was generated in SolidWorks (Figure 2.11). This version included 12 stent segments repeated in each row, and 6 rows connected
together. This is a flat version of a 3 mm diameter by 13 mm long coronary stent.
A mask was created and the design was manufactured using standard techniques described
in Chapter 1. A method for holding the flat stent in place was developed and constructed. In
this method, the stent was held in place while an Instron test machine compressed the flat stent
recording both force and displacement (Figure 2.12).
Due to complex geometry of the stent design, it was impossible to calculate the elastic
modulus, ultimate strength, or ultimate strain directly from the force/displacement data. Also,
due to the variability in CI-CNT material properties, the elastic modulus cannot be assumed to be
certain value, although it is typically near 10 GPa. The ultimate strength is generally near 150
MPa [40].
The only method to calculate the elastic modulus and ultimate strength was through an iterative process using FEA. In this process, the flat stent was compressed and the force/displacement
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Figure 2.12: Mechanical setup for compression testing a flat stent geometry. Left: uncompressed
stent. Right: Fully compressed stent.

data from the Instron was recorded. In ANSYS, an identical test was performed using an initial guess of 10 GPa for the elastic modulus. This modulus was then adjusted until the predicted
force/displacement in ANSYS matched with the results measured using the Instron.
Once the elastic modulus was determined, the ultimate strength and strain could be calculated. This was done by using a camera to record the mechanical testing. Using the camera,
and also comparing to the Instron data, the initial mechanical failure of the stent was determined.
The displacement of the stent at failure was then recorded and input into ANSYS to determine the
maximum stresses and strains at failure.
Seven stent samples were manufactured and tested using this process. The results are
compiled in Table 2.2. The results show that the average modulus of elasticity was close to 10
GPa, which was expected. However, the overall performance was worse than desired. The average
compression before failure was 33.5%. This is half of what is needed for a functioning stent. The
tensile stress at failure only averaged 55.1 MPa.
In the complete stent design there are over a hundred locations of higher stress. For most
tested samples, only one or two locations would fail early while most of the stent stayed intact.
For a complex stent geometry with many regions under high stress, the stent will typically fail
at a manufacturing defect causing a local stress concentration. It is likely that with improved
manufacturing techniques and quality control, the number and severity of manufacturing defects
can be reduced. If this is improved, then the percent compression before failure should be increased
significantly. An advantage of this stent design is that it can be tested non-destructively to ensure
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Table 2.2: Table of mechanical testing results for 7 samples including: nanotube depth, displacement to failure, max force, elastic modulus, max compressive stress and strain, max tensile stress
and strain, and the percent compression to failure.
Sample #
1
2
3
4
5
6
7
Average
St Dev
Min
Max

Depth (mm)
0.254
0.279
0.584
0.521
0.546
0.508
0.521
0.459
0.134
0.254
0.584

Displacement
(mm)
3.56
3.03
3.74
1.87
4.29
4.90
1.46
3.26
1.24
1.46
4.90

Max Force
(mN)
71.2
70.6
234.4
70.4
238.6
249.7
96.5
147.3
88.1
70.4
249.7

Elastic Mod E Max comp σ Max Tensile σ Max Comp Max Tensile ε
Percent
(Gpa)
(Mpa)
(Mpa)
ε (%)
(%)
Compression
8.2
90.2
44.9
1.10%
0.55%
36.5%
9.5
94.4
47.0
0.99%
0.49%
31.1%
12.3
142.0
70.7
1.15%
0.57%
38.3%
7.6
50.5
25.1
0.66%
0.33%
19.2%
11.7
154.8
77.0
1.32%
0.66%
44.0%
11.5
174.2
86.7
1.51%
0.75%
50.3%
13.3
68.9
34.3
0.52%
0.26%
15.0%
10.6
110.7
55.1
1.04%
0.52%
33.5%
2.2
46.6
23.2
0.35%
0.17%
12.8%
7.6
50.5
25.1
0.52%
0.26%
15.0%
13.3
174.2
86.7
1.51%
0.75%
50.3%

performance. The stent can be fully compressed several times after manufacturing to ensure that it
has no significant defects. If the stent fails during these tests then it will be discarded; if it doesn’t
fail, the stent will have proven its mechanical strength.

2.6

Cylindrical Stent Design
The same TMF geometry used in the previous section was used as a template for developing

a cylindrical stent design. Using the wrap function in SolidWorks this template was embossed onto
a 3 mm cylinder. The embossed sketch was extruded outward radially 0.1 mm. This extrusion was
repeated 11 times in a circular pattern resulting in a cylindrical ring with an inner diameter of 3
mm and an outer diameter of 3.2 mm (Figure 2.13). This ring was repeated longitudinally 5 times.
Each ring was connected longitudinally to the next ring with several thin flexible connections.
These connections allow the stent to bend and curve as it is guided through the arteries to the
intended vessel.
Due to the cylindrical nature of the stent, when radially compressed the stresses on the
outer edges are slightly higher than the inside edges. For this reason and because of the addition
of the segment connectors, the maximum tensile and compressive stresses are slightly higher than
the flat design. The compression resulted in a max tensile stress of 93.9 MPa and a compressive
stress of 171 MPa (Figure 2.14).
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Figure 2.13: CAD model of a full 3D cylindrical version of the 3 mm TMF design. Has 6 rows
with 12 repeating segments.

Figure 2.14: FEA of the cylindrical TMF design shows that the tensile stresses (1st principal) are
slightly higher on the outside edges. The design does not clash when compressed from a 3.2 mm
diameter down to 1.2 mm.

2.6.1

Bending Analysis
When a stent is inserted into a patient and guided to a target artery, it often must pass

through tortuous vessels. Therefore, one of the most important properties of a stent is that it can
bend easily and can be guided to a vessel. While a lower stiffness in the CI-CNT stent designs is
a disadvantage in keeping an artery open, this lower stiffness is a major advantage over stainless
steel and other metallic stents in bending through tortuous vessels
A simple bending analysis of the TMF design was performed. The initial analyses revealed
that high stresses can occur in the connection between stent segment rows during bending. The
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Figure 2.15: FE bending analysis of the TMF cylindrical design.

connection was modified to reduce those stresses and allow for sufficient flexibility to pass through
a bend in a coronary artery. The maximum stress predicted was 110 MPa, and the result is shown
in Figure 2.15.

2.7

Arterial Response
In order to predict the performance of a stent before it is manufactured, FE models of

a clogged coronary artery have been used in stent analyses [44–46]. These models are an extremely useful and inexpensive way to predict stent performance in a clogged artery. A model of
an atherosclerotic artery was developed and is described in the following sections. This model was
validated using an FEA of a stainless steel stent. The TMF design was also analyzed using this
model.

2.7.1

Arterial Model
A normal sized coronary artery was selected for this model. A reference diameter of 3 mm,

meaning the inner lumen diameter of an unclogged artery is approximately 3 mm, is a common
size for coronary stents. When the lumen of a clogged artery has been reduced to 1 mm or less, the
artery typically will need to be revascularized [2, 29, 30].
The design specifications for coronary stents specify that a stent must keep the artery open
to allow blood flow to the heart. The arterial inner diameter is measured as an indicator of blood
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Figure 2.16: Model of an atherosclerotic coronary artery. Left: Arterial model before dilation.
Right: Arterial model post-dilation.

flow. Plaque accumulation on the inside wall blocks blood flow. Angioplasty expands the artery
elastically and the plaque both plastically and elastically. After angioplasty, a stent is expanded to
keep the artery open. Due to the elastic nature of the artery, sufficient radial force is needed to keep
the artery open.
In order to predict the arterial response, an FE model of an atherosclerotic artery similar
to those used in other stent analyses was created [44, 45]. In both of these studies, the artery and
plaque were modeled as 0.5 mm thick hollow concentric cylinders. This is a simple, common
model for stent design.
In one study, a plaque ID of 2 mm with a 3 mm arterial ID was used [44]. In another study,
a plaque ID of 1.5 mm and an arterial ID of 2.5 mm was used [45]. These IDs are of the artery
under no internal pressure. Arterial blood pressure generally oscillates from 80 (diastolic) to 120
(systolic) mm Hg, giving an average of 100 mm Hg constant pressure in the artery. The arterial ID
under this pressure is significantly larger than at rest.
Coronary artery reference IDs typically range from 2.5 to 4 mm. Clinical trials for recently
developed stents usually begin with a simple scenario of stenting a single lesion in an average sized
vessels. The typical size in these clinical trials is a reference size of about 3 mm with a pre-dilation
minimal lumen diameter of about 1 mm and a post-dilation lumen diameter of about 2 mm [47].
The reason for the difference in diameters is that the reference diameter refers to the inner lumen diameter without any plaque growth. With plaque growth, the minimum diameter is

29

Figure 2.17: Selected model dimensions (mm). Left: Arterial model with no pressure. Right:
Arterial model with 100 mm Hg internal pressure.

reduced. During dilation the balloon permanently deforms the plaque and artery lining leaving a
minimal diameter of roughly 2 mm (Figure 2.16).
The finite element arterial model had the following dimensions at rest: Artery OD- 3.75
mm, Artery ID- 2.75 mm, Plaque OD- 2.75 mm, Plaque ID- 1.75 mm (Figure 2.17), length 6 mm.
The plaque in this model represents the plaque following pre-dilation after it has been plastically
compressed.
While many different sizes of arteries could be analyzed, these dimensions were chosen for
two reasons. First, when applying an internal pressure of 100 mm Hg, the plaque ID expands to
2.02 mm, and the artery ID expands to 2.95 mm (Figure 2.17). This is very close to the average
size for clinical trials. Also, the CI-CNT stent is designed for a 3 mm reference diameter artery.
The material parameters assigned to the arterial tissues are critical for an accurate analysis. For this analysis, we used the parameters given by Migliavacca in their analysis, which used
parameters calculated from the testing of biological tissues by Salunke [44, 48]. The mechanical
behavior of the artery and plaque were modeled using a strain energy equation for the hyperelastic
isotropic constitutive model of the following form:
U = C1 ∗ (I1 − 3) +C2 ∗ (I2 − 3)2 +C3 ∗ (I2 − 3)3

(2.1)

I1 = λ12 + λ22 + λ32 , I2 = λ12 λ22 + λ22 λ32 + λ32 λ12

(2.2)
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Figure 2.18: Left: CAD model of an atherosclerotic artery. Right: ANSYS mesh of the imported
arterial model.

Figure 2.19: Graph of the predicted pressure vs diameter response of the atherosclerotic artery
model.

In this constitutive model, I1 and I2 are strain invariants, and λ1 , λ2 , and λ3 represent the
stretch in each principal direction. For the arterial model, the following coefficients were used: C1
= .019513 MPa, C2 = 0, C3 = .02976 MPa. For the plaque: C1 = .04 MPa, C2 = .003 MPa, C3 =
.02976 MPa.
The model was generated in SolidWorks, and imported into ANSYS for analysis. Due to
the symmetric nature of the artery and plaque, only a quarter cylinder was used. The plaque and
artery were joined together sharing the same nodes. 6432 elements were used in the model mesh
(Figure 2.18). The solver accounted for large deflections due to the high pressure testing.
Pressure was applied to the inner surface of the plaque expanding the artery. Incremental
pressure steps were applied and the resulting diameters were recorded. Figure 2.19 shows the
results.
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Figure 2.20: 1/4 cylinder arterial model with a stainless steel stent.

2.7.2

Stainless Steel Stent Arterial Response
Even though this arterial model is very similar to those used in other analyses, validation

of the FE model was still necessary. To validate this model, a commonly used stainless steel stent
was modeled and analyzed to predict the artery’s response.
The selected stent was the ’Cordis BX Velocity’ which has been used in other similar
analyses [49]. The stent is made of 316L stainless steel. Its unexpanded outer diameter is 1.18
mm and it has a strut thickness of 0.14 mm (Figure 2.20). The material properties of the stent used
are those of Liang and include: Elastic modulus = 201 GPa, Poisson ratio = 0.3, yield stress = 330
MPa, limit stress = 750 MPa [45].
Pressure was applied to the inside area of the stent forcing it to expand outward to model
the balloon expansion in vivo. ANSYS contact elements were used at the interface between the
stent outside surface and the inner surface of the plaque. Solid185 elements were used allowing
plasticity with yielding beginning to occur at 330 MPa.
The stent was expanded outward to a diameter of 3.30 mm. The plaque expanded to 3.30
mm only when in contact with the stent, in other locations it expanded less. When the pressure was
removed from the stent inner surface, the stent experienced elastic recoil reducing it to a diameter
of 3.19 mm, and leaving the final minimum lumen diameter of the artery at 2.71 mm. The final
state is shown in Figure 2.21.
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Figure 2.21: Arterial response to stent angioplasty using a ’Cordis BX Velocity’ stent.

The results of this analysis gave us confidence in the FE arterial model. Several clinical
trials using the ’Cordis BX Velocity’ stent have been performed, giving information on the lumen
diameters of the target arteries before and after revascularization [2, 50]. In the 2003 study by
Moses [2], the mean diameter of the reference vessel was 2.80 mm. This is slightly less than
the 2.95 mm reference diameter of the FE arterial model under 100 mmHg pressure. After the
procedure, the minimum luminal diameter was 2.68 mm. This is slightly less than the minimum
lumen diameter of 2.71 mm predicted by the FE model.
The fact that there is good agreement between what the arterial model predicts and what is
expected from clinical trials gave us confidence that this model could be used to help predict the
performance of the TMF stent design as well as other designs being developed.

2.7.3

TMF Stent Arterial Response
The performance of a 1/4 section of the TMF stent design was analyzed using the FE

arterial model. For this design, the stent was compressed to its crimped diameter of 1.2 mm by
applying a pressure on the outer surface of the stent. The stent was then moved into the artery and
the pressure on the stent was removed allowing the stent to push out against the artery wall. The
artery was pressurized at 100 mmHg, and had an initial minimum lumen diameter of 2.00 mm.
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Figure 2.22: Arterial response to stent angioplasty using a TMF stent design (1st principal stress).

After the stent was released the artery expanded to have a minimum lumen diameter of 2.05 mm
(Figure 2.22).
One other stent design was also analyzed using this method. This design was developed
previously by Kris Jones and has an auxetic nature to allow high radial expansion without causing
a decrease in longitudinal length. Using the same methods as with TMF arterial analysis, this
auxetic stent enlarged the artery from an initial minimal lumen diameter of 2.006 mm to 2.011
mm.

2.8

Conclusion and Recommendations
This research provides a design for a full cylindrical coronary stent. The performance

has been predicted through FEA, and initial mechanical testing has been performed. One area
of concern is the ability of the TMF stent to meet the radial force/stiffness design requirements
including preventing restenosis. It is clear from the arterial response analysis that the TMF design
provides significantly less radial force than a stainless steel stent. This results in a smaller lumen
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diameter, that could result in restenosis if negative remodeling or neointimal growth occur. This
issue is discussed further in Chapter 5.

2.9

Acknowledgments
We acknowledge Clarke Capital Partners for their support and funding in part of this work.

We also thank Kristopher Jones for his collaboration in this work.

35

CHAPTER 3.

BLOOD COMPATIBILITY TESTING OF CI-CNTS1

Along with the design and testing from Chapter 2, the blood compatibility of CI-CNTs
needed to be researched and tested. Many studies have been conducted on the blood compatibility
of pyrolytic carbon which is very similar to the CI-CNT material used in this research. A summary
of those studies is included in this chapter. In addition, blood compatibility testing was performed
on CI-CNT samples manufactured for this research.

3.1

Introduction
The only known material that is completely compatible with blood is the inner lining of ar-

teries and veins known as the endothelium. The endothelium is an active material that is constantly
releasing biologically active agents that inhibit the blood’s thrombotic response. The main goal of
any blood compatible material is to limit the thrombotic response and allow endothelial cells to
cover the material limiting further thrombosis.
Pyrolytic carbon (PyC) is relatively thromboresistant material that is used in millions of mechanical heart-valves [10]. PyC is a possible candidate material for coronary stenting. However,
data is needed to quantify PyCs blood compatibility and specifically its resistance to thromboembolization.
Current data for measuring the blood compatibility of PyC as well as many other materials
is often limited to tests using stagnant blood for in vitro testing. These tests measure the amount of
thrombus generated over a period of time. Somewhat superior to these tests are experiments where
blood flows over the material at velocities and shear rates similar to in vivo conditions. However,
both types of testing are limited because they only examine the amount of thrombus formed, not
the amount of emboli that are released.
1 Much

of this chapter will be included in a journal paper submission
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The causes of material blood compatibility are understood somewhat, but many theories
are still debated. Thrombin generation and platelet activation cause intimal hyperplasia or tissue
in-growth, and can lead to restenosis and increased risk of thrombosis. Initial proteins adsorbed by
a material contacting the blood are believed to affect the platelet adhesion and interaction. Protein
adsorption is favored by electrostatic and hydrophobic interactions between the material surface
and the adsorbed protein. Albumin is an inert protein; it is predicted that when it is adsorbed
onto material surfaces it will induce less platelet adhesion and activation compared to other plasma
proteins, such as gamma-globulin and fibrinogen [51].
Animal studies of carbon-coated vascular prostheses showed improved patency rates. However, surface irregularities can contribute to poor performance. Endothelial cells release biologically active agents that limit the thrombotic response. Growing endothelial cells on synthetic
surfaces has been tried to generate a thromboresistant material [51]. Prosthesis coating with endothelial cells is an important factor for implant patency. It is important to know the mechanisms
regulating endothelium adhesion [25].
PyC has many characteristics which are unusual for biomaterials including hydrophobicity,
high surface energy, and surface roughness. These properties lead to rapid tight binding of proteins.
It is hypothesized that albumin in the blood is rapidly adsorbed on the material surface which
passivates it from platelet adhesion. Also, once albumin is absorbed it is predicted that there is
little turnover from other plasma proteins that can lead to platelet activation [9]. Platelet response
to PyC is unusual because it has extensive platelet adhesion and a high level of platelet spreading
but has minimal platelet activation and aggregation [23].
PyC has excellent durability and sufficient thromboresistance when used in mechanical
heart-valve prosthetics. Valvular prosthetics composed of PyC structural components have clinically superior levels of thromboembolic complications compared with valves made of other materials. However, PyC valve patients need chronic anticoagulation using Warfarin, and are generally
given aspirin to inhibit platelet activation. This can lead to problems if patients have bleeding
disorders because their clotting response is impaired [9].
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Figure 3.1: Formvar (left) has high level of fully spread, clustered platelets. PyC (right) has well
spread, not clustered platelets [9].

3.2

Blood Compatibility Research
There have been several studies comparing the blood compatibility of PyC to other bio-

compatible materials such as titanium.
In one study, PyC heart valve leaflets were compared to Formvar. The samples were bathed
in column-washed platelet suspension that included bovine serum albumin and incubated for 45
min at body temperature. SEM images (Figure 3.1) showed that the platelets were well spread on
the PyC, but were not higly clustered.
It is possible that well spread platelets form a monolayer that resists further platelet adhesion and thrombus formation. From the study, the extensive platelet spreading closely follows the
PyC contours. A tight monolayer of spread platelets is expected to have high strength adhesion
that would minimize embolization of the layer [9].
Another study implanted samples of PyC, titanium and cobalt-chromium into sheep vena
cava. In that study they found that the PyC had significantly larger thrombus area, and the platelet
activation was similar. This study indicated that PyC may not perform better than titanium and
cobalt chromium [24].
Another study indicated that the good anti-thrombogenic properties of PyC might be due
to the fact that it adsorbs very little Hageman factor compared to titanium and other materials.
Hageman factor is known to activate a coagulation cascade following platelet surface contact. A
low level of adsorption of albumin does not seem to contribute to PyC blood compatibility. A
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Figure 3.2: Forcefield test unit comprised of stainless steel tubing and 2 sections of pyrolytic
carbon tubing (treatment and control) [10].

high correlation was found between the total adsorbed protein content and the number of adherent
platelets. However, the activation of platelets did not depend on the amount of adsorbed protein,
but is probable that it depends on the composition of the adsorbed proteins [52].

3.3

Blood Compatibility Improvements
An ideal blood compatible material would have both hydrophobic and hydrophilic proper-

ties where it could attract proteins that increase biocompatibility and repel components that activate
platelets. ATS Medical developed a technology to attract a molecular layer of charged proteins and
lipids to the surface of PyC. To attract these components, a modulated low-voltage signal is applied
directly to PyC while it is in contact with circulating blood. They hypothesized that the attracted
blood proteins and lipids would create a surface passive to platelet activation [10].
They conducted a study where a patient’s blood passed through a flow tube that had test
samples in series. The setup had a PyC tube with the applied electric treatment followed by a
control PyC tube followed by a stainless steel tube (Figure 3.2) [10].
An electric current treatment was applied to the samples for an allotted treatment time
and then blood was allowed to flow freely for the rest of the time. The results showed that the
control PyC samples had more than 10 times the area of platelet adhesion. Visually they are easily
distinguishable.
It is possible that this treatment or similar methods can reduce platelet adhesion and subsequent thrombosis. This treatment also has the advantage of local effects, and does not alter the
systemic coagulation system like an anticoagulant drug. It is postulated that the electrically stim39

ulated PyC attracts charged blood proteins such as albumin and fibrinogen and phospholipids to
passivate the surface. It is likely that if these proteins are adsorbed, then coagulating proteins such
as Hageman factor will not adsorb to the surface. It is also possible the electric charge can alter the
fibrinogen receptors to inhibit further binding. However, some studies have shown that a pulsing
electric voltage can induce platelet activation [10].
The study by Slaughter had some very interesting results. Certainly, the thrombogenic
properties of PyC can be altered by using an electrical surface treatment. They predict that this
is because the charged surface attracts charged molecules such as albumin and fibronectin. The
visual results are very apparent between the control and treatment samples.
The existing studies that have been performed are lacking several important factors to determine whether PyC will be a good material for a coronary stent. Nearly all of the existing studies
only look at and characterize the extent of platelet activation and thrombosis without addressing
embolization.

3.4

Blood Compatibility Testing
Although there have been several studies on the blood compatibility of PyC, it was still

necessary to test the blood compatibility of the CI-CNT materials. Several initial tests were carried
out and more tests are in process. All samples were manufactured and processed by Jordan Tanner.
Thrombodyne, Inc carried out all the blood compatibility testing. My role was in coordinating and
supervising blood compatibility tests.
Three groups of material samples were analyzed using the same blood compatibility testing
method. The method used is a standard procedure at Thrombodyne where heparinized blood flows
over material samples, and the amount of thrombus formation is quantified. The manufactured
samples had a 0.91 mm square cross section and were approximately 4 cm long. Multiple materials
were tested in parallel to compare a new biomaterial to a known control sample.
The initial test group was a direct test between stainless steel and CI-CNTs. However, the
results from the first group had high variability and another group with various surface treatments
of CI-CNTs was tested. This second group gave more useful results, but more data was desired.
A final third group was tested using refined manufacturing processes for CI-CNTs. We have the
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Figure 3.3: Images of the results of the first group of testing (G1).

most confidence in this final group of samples and have included its results as well as the first two
groups.
Group 1 had two materials: CI-CNTs and stainless steel 316L. The CI-CNT samples had
a growth period of 25 min, and an infiltration period of 30 min. This was one of the initial manufacturing runs, and some of the manufacturing processes and parameters were still being refined.
The second material, stainless steel, is a common material used in coronary stents and was used
as a control. The stainless steel bars were cut out of a 0.91 mm sheet using wire EDM and then
manually sanded using 400 grit sand paper. No sanding or treatment was done to the CI-CNT
samples.
Three samples of each material were tested in the first group. The results are shown in
Table 3.1 and in Figure 3.3. This testing showed that for a small sample size the stainless steel
seemed to perform somewhat better than the CI-CNT samples. The sample size is small and the
variability between tests was high so more testing was performed.
A second group of samples were manufactured. In this group, three different surface treatments were used to try to improve the blood compatibility of the samples. The first surface treatment used a thermal oxidation method where the samples were heated in an oven while air flows
over the sample oxidizing the surface. The second surface treatment was to manually polish the
CI-CNT samples using wet 2000-grit sandpaper. The third treatment was an oxygen plasma etch
for 35 minutes in an etching chamber. The infiltration time was also increased to 60 minutes.
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Figure 3.4: Images of the results of the second group of testing (G2).

Two experiments with one sample of each CI-CNT material/treatment were tested in a head
to head comparison against the same stainless steel samples as in group 1. The results are shown in
Table 3.1 and in Figure 3.4. These results showed more promise for the CI-CNT material compared
to the stainless steel. The thermal oxidation treatment appeared to yield better results, while the
plasma etch treatment seemed to worsen the thromboresistance. In both test runs, the CI-CNT
materials had comparable blood compatibility to stainless steel. However, from examining the
samples using SEM imaging, it appeared that the samples had been infiltrated for too long causing
surface abnormalities.
A third group of samples were manufactured to gain further blood compatibility data. In
this group, the manufacturing processes were very closely monitored and the infiltration time was
decreased to 30 minutes to the prevent over-infiltration. The CI-CNT materials were treated in the
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Figure 3.5: Images of the results of the third group of testing (G3)

same manner as in group 2. Three samples in each group were compared directly to stainless steel
to test blood compatibility.
The results of group 3 are shown in Table 3.1 and in Figure 3.5. This group of samples
yielded somewhat different results than group 2. The plasma etch treatment was still the worst, but
the untreated CI-CNT samples actually outperformed any other group overall. This is encouraging
news considering that it is much simpler to not apply any treatments to the samples. If the CI-CNT
material has the best blood compatibility without any surface treatment it makes it a more desirable
biomaterial. It also appears to be equivalent too or better than the stainless steel samples.
These tests represent initial attempts to quantify the blood compatibility of CI-CNT materials compared to stainless steel. These tests had small sample sizes and there still is insufficient
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Table 3.1: Table of results of the three groups of testing (G1, G2, G3) each with 2 or 3 experiments.

Figure 3.6: Results of the three groups of testing (G1, G2, G3) each with 2 or 3 experiments. The
CI-CNT samples were manufactured under differing conditions in each group.

data to draw definite conclusions. Also, in these tests the stainless steel was not electropolished
which is the general treatment for stainless steel implants. Further tests with larger sample sizes
comparing CI-CNT materials to electropolished stainless steel 316L samples will be performed to
better quantify the blood compatibility of CI-CNTs.
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CHAPTER 4.

ADDITIONAL RESEARCH

The research included in this chapter was important to the overall success of the project,
but did not fit in well in either of the previous chapters. The first part of this chapter is focused on
developing a delivery system to guide and deploy a CI-CNT stent in a target vessel. The second
part is devoted to other design concepts that were not used in the TMF design but were analyzed
and have potential to be used in other applications.

4.1

Delivery System
Once a stent has been developed and manufactured there must be a way to deploy it. As

described in Chapter 1, in order to deploy a coronary stent, a stent delivery system with a balloon
is needed. For a typical coronary stent, a balloon is used to expand the stent radially outward
plastically deforming the stent in the desired location.
However, stents that do not undergo plastic deformation must have a different deployment
mechanism. Superelastic nitinol stents are an example of a stent that uses elastic properties to
expand outward from an initially crimped position. These stents are manufactured in an expanded
state and then elastically compressed and inserted into a catheter sheath. In order to deploy the
stent, a second smaller catheter is placed inside the sheath. This inside catheter is held in place
while the outer sheath is retracted allowing the stent to expand outward forcing the vessel open
(Figure 4.1).
A similar process could be used in deploying the TMF stent design. An initial concept is
shown in Figure 4.2. In this concept, a funnel like fixture is placed at the end of the sheath catheter.
The stent will be forced through the funnel into the sheath catheter. The stent will be placed deep
enough into the sheath catheter that the funnel can be removed without also removing or damaging
the stent. The funnel will be removed and the stent will be pushed fully into the sheath.
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Figure 4.1: Merit Medical ALIMAXX-B biliary stent being deployed [11].

Figure 4.2: Method for stent mounting. The stent is forced through the funnel into the mounting
catheter.

To deploy the stent, an inner catheter would be placed inside the sheath. The inner catheter
would have an OD only slightly smaller than the ID of the sheath. Once the stent has been positioned in the target vessel, the sheath would be retracted while holding the inner catheter in place.
This would force the stent out of the sheath, and the stent would expand elastically against the
artery inner wall.
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Figure 4.3: Section view of the stent crimped and mounted into the sheath.

4.2

Concept Development
Many concepts were generated and discussed in the initial selection and development of a

stent geometry. Some of these concepts were for an entire stent design, while others were only for
certain parts of the stent design (for example, concepts on how to connect one strut to another).
The following stent design concepts were all investigated to see their potential advantages as well
as disadvantages.

4.2.1

Locking Stent
One of the major disadvantages of using CI-CNTs in stents is that they cannot produce as

much radial force to keep clogged arteries open. One possible solution is to have the stent lock
into place. By locking into place, the stent can greatly increase the radial force and while lowering
the stress.
Figure 4.4 shows an example of a locking design. This view of the stent is in the locked
position. In order to compress, the rectangle segments would be displaced out of plane. Then the
entire stent could be 50% compressed forming a two layer stent with the rectangles in one layer
and the stent segments in another layer.
There are a few disadvantages associated with this concept. First of all, these designs can
only be compressed to a maximum of 50%. Generally, it is preferable to have the stent compress
more than that to make it easier to insert.
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Figure 4.4: The locking stent concept can achieve much higher radial force than a typical stent
design.

Another disadvantage is that currently used coronary stents (including the TMF dsign) can
be used to treat a range of arterial sizes. This design can only be used for one artery size. If the
artery is too big, the stent may not help or may be dislodged. If the artery is too small, the stent
may be unable to deploy, or could damage the artery.
The most difficult challenge of this concept is due to the fact that not all clogged artery
lumen areas are circular. The plaque may form an oval, or it may have much more plaque in one
location and none in another. This will cause a non-uniform pressure on the stent which could
cause it too buckle similar to crushing a soda can. It also may be impossible to get the stent to lock
in place if the lesion is an unusual shape. Stent buckling is a very dangerous failure mode causing
immediate thrombosis with high fatality rates.

4.2.2

Push Stent
The push stent is another concept similar to the locking stent. In this concept, the stent

would not need to be compressed to be inserted. The stent would be manufactured at the desired
size as shown in Figure 4.5. A mounting catheter with a tapered cone at the end would be used to
insert the stent. It would be positioned at the target lesion, and then would be pushed into position.
The tapered cone will expand the artery as the stent is being inserted.
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Figure 4.5: The push stent design is forced into the target lesion using a tapered cone.

This stent design would have sufficient radial force to hold open even arteries that have
severe calcified lesions. It also would perform well in non-round lesions. It would need to have
slots cut out as shown to allow the stent to flex and bend as it is guided to the target lesion.
The disadvantages of this design severely limit its use. First, since it must stay at its full
diameter during insertion, it will be very difficult to insert. Also, if the lesion is very small or
calcified it may be impossible to push the stent forward with enough force to insert it.
It also suffers in that it can only fit one size of lesion. If the lesion is too small or big, the
stent will not perform as well. However, in certain cases this design may outperform other stents,
especially when the stent material is highly blood compatible but not very flexible.

4.2.3

Torsional Spring Coil
This concept was designed to help reduce stresses that occur at the end connection between

two stent struts. Typically, stent struts are essentially a straight segment that is repeated in a
zigzag pattern and connected by a circular section. This circular section will have high stresses
during compression as shown in Chapter 2. To reduce those stresses, the length of the end circular
section was lengthened and then wrapped around itself similar to a torsional spring. This allows
the stresses to be spread out over a much longer length, reducing the maximum stress.
The torsional design does indeed lower stresses, however it also results in high tensile
stresses due to the unusual geometry and stress concentrations. Also, due to the large nature of the
torsional springs, the struts must be spaced out farther apart so that the springs do not clash into
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Figure 4.6: Torsional spring-like connection between stent struts can spread out stresses..

Figure 4.7: Highly flexible slinky-like stent design, is compressed by twisting the stent.

each other during compression. This also increases stresses. Overall, it did not seem to help the
design improve performance.

4.2.4

Slinky Stent
Another concept that was thought of is similar to a slinky. In this concept, the stent is

compressed by twisting it, and is expanded by untwisting it. This type of a design would be
extremely flexible and could be easily guided to the target artery. It could also provide very high
radial forces to keep the artery open.

51

Figure 4.8: Stent concept with struts with a wavy geometry that nest together during compression.

This stent would be difficult to deploy. It takes many twists in order to get a significant
amount of compression. To deploy the stent, some sort of rapid rotational device would be needed
to deploy it in a reasonable amount of time. The main disadvantage is that the wall thickness of
the stent must be very thin to reduce the stress sufficiently for compression. It becomes so thin that
buckling and other problems are likely to occur.

4.2.5

Nesting Stent
Another design concept is where the stent struts would have a wavy geometry where adja-

cent struts would nest together. This would increase the effective length of the struts allowing more
compression with less material strain. However, due to the curvy nature, the stress concentration
that arise cause more of a stress increase than is reduced by the extra length.

4.2.6

Design Concepts
Many other concepts were generated and investigated. Some of those concepts are included

in Appendix A.
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CHAPTER 5.

5.1

CONCLUSIONS AND RECOMMENDATIONS

Summary of Contributions
This thesis contributes in areas of design, development, and testing of a new coronary stent.

The major contributions of this thesis are: design specifications and concept generation and selection, optimization of a stent segment and a completed design of a full cylindrical coronary stent,
analysis of stent performance using mechanics of materials equations and FEA, blood compatibility research and testing.

5.1.1

Design Specifications and Selection
Information was needed to describe the properties and performance of vascular stents in

treating cardiovascular disease. The sizes and shapes of stents were discovered. Critical stent
requirements were determined including having sufficient radial force to hold a clogged artery
open. A method of deployment was created. The performance of current bare metal and drugeluting stents was quantified to have a benchmark for stent performance. This research was critical
in helping evaluate stent concepts and designs to predict their success.
Especially during the initial stages of this research, many concepts were generated and
evaluated. These concepts were explored and improved ideas were generated. As our understanding of the design requirements improved, other concepts and designs were generated and analyzed.
One design was fully completed, and several other designs also have potential to be used as well.

5.1.2

Coronary Stent Development and Optimization
The selected stent design was completed and analyzed. First, a basic repeating segment

was optimized using an exhaustive search method in MATLAB. Then, this segment was further
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optimized using FEA. Finally, a full 3-dimensional cylindrical geometry was generated including
connections between stent struts and a method for insertion into the body.

5.1.3

Finite Element Methods and Testing
The TMF stent design was analyzed several different ways. Using MATLAB, a computa-

tional analysis of stresses and forces performed. The performance of this design was also evaluated
using FEA. To help evaluate the performance of a stent design, an atherosclerotic arterial model
was created in ANSYS. This model includes a plaque area that represents an average lesion. This
model was validated by testing a stainless steel stent design with known performance and verifying the results. The CI-CNT stent designs can be easily inserted into this model and analyzed in
ANSYS to predict their performance. A current stent design can also be explored using different
material properties to see how it effects the results (for example, if the elastic modulus is 20 GPa
instead of 10 GPa).

5.1.4

Blood Compatibility Testing
Information is needed to predict the biocompatibility of any medical device before it is

implanted. The current studies on the blood compatibility of pyrolytic carbon were researched
and summarized. Methods for testing the blood compatibility of the CI-CNTs material used in the
stent designs were determined. We collaborated with two blood compatibility testing laboratories
including Ken Solen’s group at BYU, as well as Thrombodyne to perform testing. Blood compatibility testing has been and will continue to be tested and some of the results are included in this
thesis.

5.2

Discussion
This thesis work presents a coronary stent design that has been developed, optimized, and

tested. The hope of this research is that it will be used to develop a new stent product to improve
medical treatments. An improved stent design could be used to save lives and improve quality of
life. However, the performance of these designs must be examined critically to compare to existing
coronary stents.
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This research answers many questions about the performance of the CI-CNT stent designs.
There are two open questions that this research partially addressed but are worthy of further research: how much radial force is enough, and is the blood compatibility good enough. These two
questions are critical to stent success and are discussed in the following sections.

5.2.1

How Much Radial Force is Enough?
The primary function of a stent is to prevent the artery from closing off following balloon

angioplasty. When the artery is closed off quickly (heart attack) it is highly fatal. If the artery
closes off slowly (restenosis) then the artery will need to be revascularized. This is a non-fatal but
unfavorable outcome, and currently occurs in a significant percentage of procedures.
As described in the background section, restenosis is caused by three factors: elastic recoil
of the artery following balloon expansion, negative remodeling of the artery causing the arterial ID
to shrink, and intimal tissue growth further occluding the vessel. However, our current understanding of the relative extent that each of these three factors contributes to restenosis is incomplete. In
general, existing coronary stents have made substantial progress in addressing the first two causes,
although they often have difficulty preventing intimal hyperplasia.
The TMF stent design was optimized to provide as much radial force as possible to keep the
artery open within the design space described previously. However, the lower material toughness
(strain energy to failure) of the CI-CNT material constrains the magnitude of elastic recoil resisted
by the TMF design. The magnitude of radial force required to maintain sufficient vessel lumen is
currently unknown. It is likely that the TMF design will outperform existing stents in preventing
intimal tissue growth. Implanting the TMF stent will also be less traumatic to the coronary artery
which will further reduce the intimal hyperplasia response.
If future work determines that higher radial force is needed to maintain the lumen of the
blood vessel, there are opportunities to improve the CI-CNT material properties. It is likely that
with improved manufacturing processes the elastic modulus and strength of the CI-CNT material
could be improved, increasing the stent radial force. Also, in future research, carbon nanotubes
could be aligned in multiple directions which would greatly increase the stiffness and strength of
CI-CNTs. Another approach for improving radial force may be in developing alternative design
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concepts that include a locking mechanism to provide greater force (some of these are presented
in Chapter 4 and in the Appendix A of this thesis).
In many cases, existing stents appears to have more radial force than is necessary to keep an
artery open. In most cases, balloon angioplasty alone prevents restenosis due to the small amount
of negative remodeling and intimal hyperplasia that occurs. In all cases, balloon angioplasty alone
prevents restenosis for short duration. If the stent could remain in this open state permanently there
would be no complications. This indicates that even if a stent does not fully prevent artery elastic
recoil, if it can eliminate negative remodeling and intimal hyperplasia it will prevent restenosis. It
is possible that this design or similar designs will be best used in targeted applications in coronary
stenting, and possibly in other vascular areas.

5.2.2

Is the Blood Compatibility Good Enough?
The blood compatibility of the CI-CNTs is critical for stent performance. Initial blood

compatibility testing indicates that the CI-CNT material has similar properties to stainless steel.
Also, these tests have shown that the blood compatibility of the CI-CNT material is sensitive to
manufacturing technique. The most recent set of tests (Group 3) confirms that the material may be
able to outperform stainless steel by a significant margin. However, there is still substantial work
to be done before the potential for blood compatibility improvements can be determined.
The majority of coronary stents used currently are drug-eluting stents. Drug-eluting stents
are an active material releasing anti-thrombic drugs locally to inhibit the blood’s response and
improve compatibility. In general, it is difficult for a passive material such as CI-CNTs to compete
with an active material. However, it is possible to improve the biocompatibility of CI-CNTs in
ways that cannot be done to stainless steel or other stent materials. One unique advantage that CICNTs have is the ability to be infiltrated with polymers including drug-eluting resorbable polymers
due to the porous nature of CI-CNTs. Bare-metal stents do not have this ability. They can only be
coated with a polymer that will wear off and eventually disappear. This ability to be infused with
anti-thrombic resorbable polymers could lead to a major advantage over bare-metal stents.
It is also possible to drastically improve the blood compatibility of CI-CNTs using a process similar to the electrically treated pyrolytic carbon described in Chapter 3. This relatively
new technology developed to manufacture stent geometries made of CI-CNTs combined with the
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recent technique of improving blood compatibility could produce a vascular stent capable of outperforming any other stent in targeted applications. However, the technique for improving blood
compatibility is not fully developed, and additional research would be required to investigate this
potential.

5.3

Conclusion
This research has produced a promising CI-CNT stent design, along with methods to pre-

dict the performance of various stent geometries. Initial mechanical testing and blood compatibility
studies are encouraging. There is also information provided on stent performance requirements,
along with research on the necessary blood compatibility. Additional research in both design and
blood compatibility are needed before commercialization of CI-CNT stent technology.
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APPENDIX A.

CONCEPT GENERATION
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Figure A.1: Stent segments can be connected in-line with each other, or in an opposite configuration.
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Figure A.2: It may be possible to use stainless steel struts to plastically expand the stent but use
PyC to hold contact the arterial wall.
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Figure A.3: It may be beneficial to connect stent segments sideways, or to use two thinner connections.
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Figure A.4: It may be possible to have locking design that has multiple sizes using a sort of
staircase design.
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APPENDIX B.

BASIC STENT ANALYSIS MATLAB CODE

% Darrell Skousen
% Stent Segment Analysis
clc
clear
%Input Parameters
theta = [30]*pi/180;
R = [.05]*10^-3;
phi = [80]*pi/180;
L = [1]*10^-3;
thick = [25]*10^-6;
depth = .025E-3;
%Test Parameters
F = .405E-3;
for i = 1:1
for j = 1:1
for k = 1:1
for m = 1:1
for n = 1:1
%Calculated Parameters
phi2(i,k) = theta(i) - 2*phi(k) + pi;
phi3(i,k) = phi(k) - theta(i)/2;
phi4(i,k) = 2*pi - phi2(i,k);
phi5(i,k) = pi/2 - phi2(i,k)/2;
alpha2(i,k) = phi4(i,k) - phi5(i,k);
alpha1(i,k) = -phi5(i,k);
L1(i,m) = L(m)/2*cos(theta(i)/2);
% Mc(i,m) = F*L1(i,m);
Mc(i,m) = F*L(m)/2;
cp(i,k) = cos(phi5(i,k));
sp(i,k) = sin(phi5(i,k));
int(i,k) = phi4(i,k)/2;
I(n) = depth*thick(n)^3/12;
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E = 10E9;
A(n) = depth*thick(n);
%Calculate deflection of circle
%
Dc(i,j,k,m,n) = F*R(j)/(E*A(n))*(cp(i,k)^2*(int(i,k)/2
%-sin(2*int(i,k))/4)+2*sp(i,k)*cp(i,k)*(-cos(int(i,k))-sin(int(i,k))^2/2)...
%
+sp(i,k)^2*(1.5*int(i,k)-2*sin(int(i,k))+sin(2*int(i,k))/2))
%+F*R(j)^3/(E*I(n))*(cp(i,k)^2*((int(i,k)/2)...
% -sin(2*int(i,k))/4)+2*sp(i,k)*cp(i,k)*(-cos(int(i,k))
%-sin(int(i,k))^2/2)+sp(i,k)^2*(1.5*int(i,k)-2*sin(int(i,k))...
%
+sin(2*int(i,k))/2)-Mc(i,m)*cp(i,k)*cos(int(i,k))+Mc(i,m)*sp(i,k)*(int(i,k)
-sin(int(i,k)))+2*sp(i,k)*cp(i,k)+Mc(i,m)*cp(i,k));
Dc1 = F*R/(E*A)*(cp^2*(int/2-sin(2*int)/4)-2*sp*cp*(sin(int)^2/2)
+sp^2*(int/2+sin(2*int)/4))...
+F*R^3/(E*I)*(cp^2*((int/2)-sin(2*int)/4)+2*sp*cp*(-cos(int)
-sin(int)^2/2)+sp^2*(1.5*int-2*sin(int)...
+sin(2*int)/2)+Mc/(F*R)*cp*cos(int)-Mc/(F*R)*sp*(int-sin(int)));
Dc2 = -(F*R/(E*A))*2*sp*cp+(F*R^3/(E*I))*Mc/(F*R)*cp;
Dc = -(Dc1-Dc2);
alpha_t(i,j,k,m,n) = Dc(i,j,k,m,n)/R(j);
alpha_degrees(i,j,k,m,n) = alpha_t(i,j,k,m,n).*180/pi
%check alpha_t
Mf=F*(L(m)/2+R(j));
Ro(i,m,n) = E*I(n)/Mf(i,m);
Lr(i,j,k) = R(j)*phi4(i,k)/2;
alpha_tm(i,j,k,m,n) = Lr(i,j,k)/Ro(i,m,n);
alpha_tm_deg(i,j,k,m,n) = Lr(i,j,k)/Ro(i,m,n)*180/pi
%Parameters for beam deflection
beta(i,j,k,m,n) = theta(i)/2-alpha_t(i,j,k,m,n);
Lp(m) = L(m)/2;
nn(i,j,k,m,n) = tan(beta(i,j,k,m,n));
phi_p(i,j,k,m,n) = beta(i,j,k,m,n) + pi/2;
ktheta = 2.65;
syms var
expr(i,j,k,m,n) = var - F*sin(phi_p(i,j,k,m,n)-var)*Lp(m)^2/(E*I(n)*ktheta);
thetaC(i,j,k,m,n) = solve(expr(i,j,k,m,n),var);
gamma(i,j,k,m,n) = (.8521 - .01829*nn(i,j,k,m,n));
c(i,j,k,m,n) = gamma(i,j,k,m,n)*Lp(m)*(1-cos(thetaC(i,j,k,m,n)));
b(i,j,k,m,n) = gamma(i,j,k,m,n)*Lp(m)*sin(thetaC(i,j,k,m,n));
Dp(i,j,k,m,n) = (c(i,j,k,m,n)^2 + b(i,j,k,m,n)^2)^.5;
beta_p(i,j,k,m,n) = tan(c(i,j,k,m,n)/b(i,j,k,m,n));
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Db(i,j,k,m,n) = Dp(i,j,k,m,n)*cos(beta(i,j,k,m,n)-beta_p(i,j,k,m,n));
% Db(i,j,k,m,n) = double(Db(i,j,k,m,n));
Db_check(m,n) = F*Lp(m)^3/(3*E*I(n));
angle_check(m,n) = F*Lp(m)^2/(2*E*I(n))*180/pi;
% Deflection due to anglular deflection
% theta_v(i,j,k,m,n) = theta(i)/2 - alpha_t(i,j,k,m,n);
theta_v(i,j,k,m,n) = theta(i)/2 - alpha_tm(i,j,k,m,n);
Dt(i,m) = Lp(m)*sin(theta(i)/2)
Lt(i,m) = Lp(m)*cos(theta(i)/2);
Lh(i,j,k,m,n) = Lt(i,m)/cos(theta_v(i,j,k,m,n));
Dv(i,j,k,m,n) = Lh(i,j,k,m,n)*sin(theta_v(i,j,k,m,n));
Da(i,j,k,m,n) = Dt(i,m)-Dv(i,j,k,m,n);
D1(i,j,k,m,n) = Da(i,j,k,m,n)+Db(i,j,k,m,n)+Dc(i,j,k,m,n);
D4(i,j,k,m,n) = D1(i,j,k,m,n)*4;
%Stress
% Lm(j,m) = Lp(m) + 2*R(j);
Lm(j,m) = Lp(m) + R(j)+R(j)*sin(phi4/2-pi/2);
M(j,m) = F*Lm(j,m);
stress_straight(j,m,n) = M(j,m)*thick(n)/(2*I(n))
%Length ratios
Dmax(i,j,m) = 2*L(m)*sin(theta(i)/2)+4*R(j)*sin(theta(i)/2);
Dmin(j) = 4*R(j)+2*thick(n);
Dratio(i,j,m) = Dmax(i,j,m)/Dmin(j);
Dcomp(i,j,k,m,n) = (Dmax(i,j,m)-D4(i,j,k,m,n))/Dmax(i,j,m);
%Curved Beam Stress
dAr(j,n) = depth*log((R(j)+thick(n)/2)/(R(j)-thick(n)/2));
rn(j,n) = A(n)/dAr(j,n);
e(j,n) = R(j)-rn(j,n);
rt(j,n) = R(j)+thick(n)/2;
rc(j,n) = R(j)-thick(n)/2;
stresst(j,m,n) = -M(j,m)*(rn(j,n)-rt(j,n))/(A(n)*e(j,n)*rt(j,n))-F/A(n);
stressc(j,m,n) = -M(j,m)*(rn(j,n)-rc(j,n))/(A(n)*e(j,n)*rc(j,n))-F/A(n);
%Optimize
Opt(i,j,k,m,n) = Dcomp(i,j,k,m,n)*(stresst(j,m,n))*Lm(j,m);
end
end
end
end
end
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stresst
stressc
D4
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APPENDIX C.

C.1

ANSYS CODE

TMF Stent Cylindrical Analysis

/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
/clear
/PREP7
ET,1,SOLID185
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,12.5E9
MPDATA,PRXY,1,,.3
~PARAIN,’Stent tapered curved select_b’,’x_t’,,SOLIDS,0,0
VSWEEP,1,20,39
FINISH
/SOLU
DA,100,UX,
DA,7,UZ,
DL,280, ,UY,
DL,8, ,UY,
SFA,20,1,PRES,25000
NLGEOM,ON
SOLVE
FINISH
/POST1
/DSCALE,1,1.0
/EFACET,1
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PLNSOL, U,X, 0,1.0

C.2

TMF Stent Flat Analysis

/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
FINISH
/clear
/PREP7
ET,1,SOLID185
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,10E9
MPDATA,PRXY,1,,.3
~PARAIN,’Stent tapered select_c’,’x_t’,,SOLIDS,0,0
/NOPR
/GO
ESIZE,.000015,0,
CM,_Y,VOLU
VSEL, , , ,
1
CM,_Y1,VOLU
CMSEL,S,_Y
VSWEEP,_Y1
CMDELE,_Y
CMDELE,_Y1
CMDELE,_Y2
finish
!Set boundary conditions and loads
/SOL
FLST,2,1,4,ORDE,1
FITEM,2,155
/GO
DL,P51X, ,UX,
FLST,2,1,4,ORDE,1
FITEM,2,155
/GO
DL,P51X, ,UY,
FLST,2,1,4,ORDE,1
FITEM,2,155
/GO
DL,P51X, ,UZ,
FLST,2,1,4,ORDE,1
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FITEM,2,61
/GO
DL,P51X, ,UX,-1048e-006
FLST,2,1,4,ORDE,1
FITEM,2,61
/GO
DL,P51X, ,UY,0
FLST,2,1,4,ORDE,1
FITEM,2,61
/GO
DL,P51X, ,UZ,0
!Solve
nlgeom,on
solve
finish
/POST1
/DSCALE,1,1.0

C.3

Stent Basic Segment Analysis

!/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
/clear
/PREP7
ET,1,SOLID186
!ET,1,SOLID187
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,10E9
MPDATA,PRXY,1,,.3
!Define Parameters
pi=acos(-1)
theta=30*pi/180
rad=.05E-3
phi=80*pi/180
len=1E-3
thk=.025E-3
phi2=theta-2*phi+pi
ff=.05E-3
deep=.0125E-3
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!Create Geometry
k,1,0,0,0
k,2,sin(theta/2)*len/2,-cos(theta/2)*len/2,0
KWPAVE,2
CSYS,4
k,3,rad*sin(phi2/2)*2,0,0
k,4,rad*sin(phi2/2),-rad-cos(phi2/2)*rad,0
LSTR,1,2
LARC,2,4,1,rad,
KWPAVE,3
CSYS,4
k,5,sin(theta/2)*len,cos(theta/2)*len,0
LARC,3,4,5,rad,
LSTR,3,5
KWPAVE,5
CSYS,4
k,6,rad*sin(phi2/2)*2,0,0
k,7,rad*sin(phi2/2),rad+rad*cos(phi2/2),0
KWPAVE,6
CSYS,4
k,8,sin(theta/2)*len/2,-cos(theta/2)*len/2,0
CSYS,0
WPAVE,0,0,0
CSYS,0
LARC,5,7,3,rad,
LARC,6,7,8,rad,
LSTR,6,8
LPLOT
k,9,-cos(theta/2)*thk/2,-sin(theta/2)*thk/2,0
k,10,cos(theta/2)*thk/2,sin(theta/2)*thk/2,0
LSTR,9,1
LSTR,1,10
k,11,0,0,-deep
k,12,0,0,deep
LSTR,1,11
LSTR,1,12
ADRAG,8,9 , , , , ,
10
ADRAG,8,9 , , , , ,
11
AADD,1,2,3,4
LFILLT,1,2,ff, ,
LFILLT,3,4,ff, ,
LFILLT,4,5,ff, ,
LFILLT,6,7,ff, ,
FLST,8,11,4
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FITEM,8,1
FITEM,8,8
FITEM,8,2
FITEM,8,3
FITEM,8,9
FITEM,8,4
FITEM,8,14
FITEM,8,5
FITEM,8,6
FITEM,8,19
FITEM,8,7
VDRAG,
5, , , , , ,P51X
FLST,2,11,6,ORDE,2
FITEM,2,1
FITEM,2,-11
VADD,P51X
!Meshing Elements
ESIZE,thk/6
VSWEEP,12
!VMESH,12
FINISH
/SOL
dd=.4007*1E-3 !Deflection
!Fix one side
DL,13, ,UX,
DL,18, ,UX,
DL,13, ,UY,
DL,18, ,Uy,
DL,13, ,Uz,
DL,18, ,Uz,
DL,189, ,UX,-dd !Deflect other side
DL,191, ,UX,-dd
DL,189, ,Uy,
DL,191, ,Uy,
DL,189, ,Uz,
DL,191, ,Uz,
NLGEOM,ON !Turn on non-linear geometry
SOLVE
FINISH
/POST1
/DSCALE,1,1.0
PLNSOL, S,X, 0,1.0
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C.4

TMF Stent Arterial Analysis

/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
/clear
/PREP7
ET,1,SOLID185
MPTEMP,,,,,,,,
MPTEMP,1,0
!MPDATA,EX,3,,12.5E9
MPDATA,EX,3,,10E9
MPDATA,PRXY,3,,.3
!PP=25000
PP=20000
PP80=10.66E3
PP100=13.33E3
PP120=16.00E3
TB,HYPE,1,1,9,MOON
TBTEMP,0
TBDATA,,.019513E6,,,,,
TBDATA,,,,.02976E6,,,
TB,HYPE,2,1,9,MOON
TBTEMP,0
TBDATA,,.04E6,,,,.003E6,
TBDATA,,,,.02976E6,,,
~PARAIN,’Arterial Model pyrolytic’,’x_t’,,SOLIDS,0,0
VSEL,,,,3
VATT,3,,1
VSWEEP,3,51,32
ALLSEL,ALL

VGLUE,1,2
ESIZE,.00015,0,
VSEL,,,,1
VATT,1,,1
VSWEEP,1
ALLSEL,ALL
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VSEL,,,,4
VATT,2,,1
VSWEEP,4
ALLSEL,ALL
FINISH
/SOLU
!Nothing happening
DA,19,UX,
DA,126,UX,
DA,4,UX,
DA,112,UY,
DA,125,UY,
DA,2,UY,
DA,127,UZ,
DA,5,UZ,
DA,128,UZ,
DA,4,UZ,
LSWRITE,1,
!Arterial pressure added to 80 mmHg
SFA,7,1,PRES,PP80
NLGEOM,ON
LSWRITE,2,
!Arterial pressure added to 120 mmHg
SFA,7,1,PRES,PP120
LSWRITE,3,
!Arterial pressure down to 100 mmHg
SFA,7,1,PRES,PP100
LSWRITE,4,
!Compress stent
DL,304, ,UZ,
DL,32, ,UZ,
SFA,32,1,PRES,PP
LSWRITE,5,
DL,304, ,UZ,-.0025
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DL,32, ,UZ,-.0025
LSWRITE,6,
FINISH
/PREP7
!*
!*
/COM, CONTACT PAIR CREATION - START
CM,_NODECM,NODE
CM,_ELEMCM,ELEM
CM,_KPCM,KP
CM,_LINECM,LINE
CM,_AREACM,AREA
CM,_VOLUCM,VOLU
/GSAV,cwz,gsav,,temp
MP,MU,3,
MAT,3
MP,EMIS,3,7.88860905221e-031
R,3
REAL,3
ET,2,170
ET,3,174
R,3,,,1.0,0.1,0,
RMORE,,,1.0E20,0.0,1.0,
RMORE,0.0,0,1.0,,1.0,0.5
RMORE,0,1.0,1.0,0.0,,1.0
KEYOPT,3,4,0
KEYOPT,3,5,0
KEYOPT,3,7,0
KEYOPT,3,8,0
KEYOPT,3,9,0
KEYOPT,3,10,2
KEYOPT,3,11,0
KEYOPT,3,12,0
KEYOPT,3,2,0
KEYOPT,2,5,0
! Generate the target surface
ASEL,S,,,32
CM,_TARGET,AREA
TYPE,2
NSLA,S,1
ESLN,S,0
ESLL,U
ESEL,U,ENAME,,188,189
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NSLE,A,CT2
ESURF
CMSEL,S,_ELEMCM
! Generate the contact surface
ASEL,S,,,7
CM,_CONTACT,AREA
TYPE,3
NSLA,S,1
ESLN,S,0
NSLE,A,CT2 ! CZMESH patch (fsk qt-40109 8/2008)
ESURF
ALLSEL
ESEL,ALL
ESEL,S,TYPE,,2
ESEL,A,TYPE,,3
ESEL,R,REAL,,3
/PSYMB,ESYS,1
/PNUM,TYPE,1
/NUM,1
EPLOT
ESEL,ALL
ESEL,S,TYPE,,2
ESEL,A,TYPE,,3
ESEL,R,REAL,,3
CMSEL,A,_NODECM
CMDEL,_NODECM
CMSEL,A,_ELEMCM
CMDEL,_ELEMCM
CMSEL,S,_KPCM
CMDEL,_KPCM
CMSEL,S,_LINECM
CMDEL,_LINECM
CMSEL,S,_AREACM
CMDEL,_AREACM
CMSEL,S,_VOLUCM
CMDEL,_VOLUCM
/GRES,cwz,gsav
CMDEL,_TARGET
CMDEL,_CONTACT
/COM, CONTACT PAIR CREATION - END
/MREP,EPLOT
/SOLU
SFA,32,1,PRES,PP*1/2
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LSWRITE,7,
SFA,32,1,PRES,0
LSWRITE,8,
LSSOLVE,1,8,1
FINISH
/POST1
/DSCALE,1,1.0
/EFACET,1
PLNSOL, S,1, 2,1.0

C.5

Staniless Stent Cylindrical Analysis

/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
FINISH
/clear
/PREP7
ET,1,SOLID185
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,201E9
MPDATA,PRXY,1,,.3
TBDE,PLAS1,1,,,
TB,PLAS,1,1,9,MISO
TBTEMP,0
TBPT,,0,0
TBPT,,0.0016418,3.3E+008
TBPT,,0.005,3.5E+008
TBPT,,0.01,3.7E+008
TBPT,,0.03,4.2E+008
TBPT,,0.1,5.5E+008
TBPT,,0.2,6.75E+008
TBPT,,0.3,7.25E+008
TBPT,,0.4,7.5E+008
~PARAIN,’stainless balloon’,’x_t’,,SOLIDS,0,0
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ESIZE,.00004,0,
CM,_Y,VOLU
VSEL, , , ,
CM,_Y1,VOLU
CHKMSH,’VOLU’
CMSEL,S,_Y
VSWEEP,_Y1
CMDELE,_Y
CMDELE,_Y1
CMDELE,_Y2

1

FINISH
/SOL
DA,13,UX,
DA,30,UY,
DK,40, , , ,0,UZ, , , , , ,
LSWRITE,1,

FLST,2,9,5,ORDE,8
FITEM,2,1
FITEM,2,11
FITEM,2,-12
FITEM,2,14
FITEM,2,24
FITEM,2,-26
FITEM,2,37
FITEM,2,-38
SFA,P51X,1,PRES,1.2E6
LSWRITE,2,

FLST,2,9,5,ORDE,8
FITEM,2,1
FITEM,2,11
FITEM,2,-12
FITEM,2,14
FITEM,2,24
FITEM,2,-26
FITEM,2,37
FITEM,2,-38
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SFA,P51X,1,PRES,1.645E6
LSWRITE,3,
FLST,2,9,5,ORDE,8
FITEM,2,1
FITEM,2,11
FITEM,2,-12
FITEM,2,14
FITEM,2,24
FITEM,2,-26
FITEM,2,37
FITEM,2,-38
SFA,P51X,1,PRES,0
LSWRITE,4,
LSSOLVE,1,4,1
FINISH
/POST1
/DSCALE,1,1.0
/REPLOT
/EFACET,1
PLNSOL, U,X, 0,1.0

C.6

Stainless Stent Arterial Analysis

/CWD,’C:\Users\Darrell\Dropbox\Thesis\Thesis J’
FINISH
/clear
/PREP7
ET,1,SOLID185
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,201E9
MPDATA,PRXY,1,,.3
PP=2E6
pi=3.14159
TBDE,PLAS1,1,,,
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TB,PLAS,1,1,9,MISO
TBTEMP,0
TBPT,,0,0
TBPT,,0.0016418,3.3E+008
TBPT,,0.005,3.5E+008
TBPT,,0.01,3.7E+008
TBPT,,0.03,4.2E+008
TBPT,,0.1,5.5E+008
TBPT,,0.2,6.75E+008
TBPT,,0.3,7.25E+008
TBPT,,0.4,7.5E+008
~PARAIN,’stainless balloon’,’x_t’,,SOLIDS,0,0
ESIZE,.00009,0,
ndiv=8
FLST,5,6,4,ORDE,6
FITEM,5,11
FITEM,5,-12
FITEM,5,33
FITEM,5,-34
FITEM,5,61
FITEM,5,-62
CM,_Y,LINE
LSEL, , , ,P51X
CM,_Y1,LINE
CMSEL,,_Y
LESIZE,_Y1, , ,ndiv, , , , ,1
ndiv2=6
LESIZE,37, , ,ndiv2, , , , ,1
LESIZE,29, , ,ndiv2, , , , ,1
LESIZE,8, , ,ndiv2, , , , ,1
LESIZE,14, , ,ndiv2, , , , ,1
LESIZE,65, , ,ndiv2, , , , ,1
LESIZE,57, , ,ndiv2, , , , ,1
VSWEEP,1
!Import artery and plaque
TB,HYPE,2,1,9,MOON
TBTEMP,0
TBDATA,,.019513E6,,,,,
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TBDATA,,,,.02976E6,,,
TB,HYPE,3,1,9,MOON
TBTEMP,0
TBDATA,,.04E6,,,,.003E6,
TBDATA,,,,.02976E6,,,
!ET,2,SOLID185
!MPTEMP,,,,,,,,
!MPTEMP,1,0
!MPDATA,EX,2,,1E9
!MPDATA,PRXY,2,,.3
!ET,3,SOLID185
!MPTEMP,,,,,,,,
!MPTEMP,1,0
!MPDATA,EX,3,,1E9
!MPDATA,PRXY,3,,.3
~PARAIN,’Arterial Model_b’,’x_t’,,SOLIDS,0,0
VGLUE,2,3
ESIZE,.00012
dd1=.00024
dd2=.00012
LESIZE,92,dd2, , , , , , ,1
LESIZE,100,dd2, , , , , , ,1
LESIZE,89,dd2, , , , , , ,1
LESIZE,96,dd2, , , , , , ,1
LESIZE,101,dd1,
LESIZE,103,dd1,
LESIZE,102,dd1,
LESIZE,104,dd1,
LESIZE,81,dd1,
LESIZE,83,dd1,
LESIZE,85,dd1,
LESIZE,87,dd1,
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,1
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VSEL,,,,2
VATT,2,,1,0
VSWEEP,2
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VSEL,,,,4
VATT,3,,1,0
VSEL, , , ,
VSWEEP,4

4

ALLSEL,ALL
/COM, CONTACT PAIR CREATION - START
CM,_NODECM,NODE
CM,_ELEMCM,ELEM
CM,_KPCM,KP
CM,_LINECM,LINE
CM,_AREACM,AREA
CM,_VOLUCM,VOLU
/GSAV,cwz,gsav,,temp
MP,MU,1,
MAT,1
R,3
REAL,3
ET,2,170
ET,3,174
KEYOPT,3,9,0
KEYOPT,3,10,2
R,3,
RMORE,
RMORE,,0
RMORE,0
! Generate the target surface
ASEL,S,,,8
ASEL,A,,,9
ASEL,A,,,10
ASEL,A,,,21
ASEL,A,,,22
ASEL,A,,,23
ASEL,A,,,34
ASEL,A,,,35
ASEL,A,,,36
CM,_TARGET,AREA
TYPE,2
NSLA,S,1
ESLN,S,0
ESLL,U
ESEL,U,ENAME,,188,189
NSLE,A,CT2
ESURF
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CMSEL,S,_ELEMCM
! Generate the contact surface
ASEL,S,,,45
CM,_CONTACT,AREA
TYPE,3
NSLA,S,1
ESLN,S,0
NSLE,A,CT2 ! CZMESH patch (fsk qt-40109 8/2008)
ESURF
ALLSEL
ESEL,ALL
ESEL,S,TYPE,,2
ESEL,A,TYPE,,3
ESEL,R,REAL,,3
/PSYMB,ESYS,1
/PNUM,TYPE,1
/NUM,1
EPLOT
ESEL,ALL
ESEL,S,TYPE,,2
ESEL,A,TYPE,,3
ESEL,R,REAL,,3
CMSEL,A,_NODECM
CMDEL,_NODECM
CMSEL,A,_ELEMCM
CMDEL,_ELEMCM
CMSEL,S,_KPCM
CMDEL,_KPCM
CMSEL,S,_LINECM
CMDEL,_LINECM
CMSEL,S,_AREACM
CMDEL,_AREACM
CMSEL,S,_VOLUCM
CMDEL,_VOLUCM
/GRES,cwz,gsav
CMDEL,_TARGET
CMDEL,_CONTACT
/COM, CONTACT PAIR CREATION - END
/MREP,EPLOT
/COM, CONTACT PAIR PROPERTIES - START
RMODIF,3,3,.2
RMODIF,3,4,0.1
KEYOPT,3,4,2
/COM, CONTACT PAIR PROPERTIES - END
/MREP,EPLOT
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!*Define loads
!*First Step
FINISH
/SOL
DA,51,UY,
DA,40,UY,
DA,30,UY,
DA,13,UX,
DA,52,UX,
DA,42,UX,
DA,53,UZ,
DA,43,UZ,
DA,54,UZ,
DA,44,UZ,
FINISH
/PREP7
!FLST,4,2,1,ORDE,2
!FITEM,4,354
!FITEM,4,2855
!CP,1,UZ,P51X
FLST,4,154,1,ORDE,18
FITEM,4,514
FITEM,4,-553
FITEM,4,680
FITEM,4,-681
FITEM,4,701
FITEM,4,721
FITEM,4,760
FITEM,4,-761
FITEM,4,781
FITEM,4,801
FITEM,4,1182
FITEM,4,-1201
FITEM,4,1582
FITEM,4,-1601
FITEM,4,2865
FITEM,4,-2867
FITEM,4,2925
FITEM,4,-2987
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CP,2,UZ,P51X
FLST,4,154,1,ORDE,4
FITEM,4,554
FITEM,4,-641
FITEM,4,2742
FITEM,4,-2807
CP,3,UZ,P51X
FINISH
/SOL
D,486, ,0, , , ,UZ, , , , ,
!D,354, ,0, , , ,UZ, , , , ,
!D,2855, ,0, , , ,UZ, , , , ,

PP2=100000
SFA,45,1,PRES,PP2*.133
NLGEOM,ON
LSWRITE,1,
SFA,45,1,PRES,PP2
dd=.1
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,2,
dd=.5
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,3,
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dd=.9
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,4,
dd=1
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,5,

dd=0
SFA,45,1,PRES,PP2*.9
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,6,
dd=0
SFA,45,1,PRES,PP2*.8
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
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SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,7,
dd=0
SFA,45,1,PRES,PP2*.7
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,8,
dd=0
SFA,45,1,PRES,PP2*.6
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,9,
dd=0
SFA,45,1,PRES,PP2*.5
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,10,
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dd=0
SFA,45,1,PRES,PP2*.4
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,11,
dd=0
SFA,45,1,PRES,PP2*.35
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,12,
dd=0
SFA,45,1,PRES,PP2*.3
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,13,
dd=0
SFA,45,1,PRES,PP2*.25
SFA,24,1,PRES,PP*dd
SFA,25,1,PRES,PP*dd
SFA,14,1,PRES,PP*dd
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SFA,1,1,PRES,PP*dd
SFA,12,1,PRES,PP*dd
SFA,11,1,PRES,PP*dd
SFA,37,1,PRES,PP*dd
SFA,38,1,PRES,PP*dd
SFA,26,1,PRES,PP*dd
LSWRITE,14,
dd=0
SFA,45,1,PRES,PP2*.2
LSWRITE,15,
!NSUBST,400,0,0
SFA,45,1,PRES,PP2*.1333
LSWRITE,16,
!Solve
LSSOLVE,1,16,1,
FINISH
/POST1
/DSCALE,1,1.0
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